Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 132 participants.

Also called NCT01346215

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 132 participants (planned count) (from the registry)
Sponsor
Laboratório Químico Farmacêutico Bergamo Ltda. (from the registry)
Registry
  • NCT NCT01346215
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01346215. Randomized; single masking; primary purpose prevention. Start 2011-10 (registry gives no type); primary completion 2011-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure
Condition
Chronic Renal Failure
Intervention (Biological)
heparin sodium
Intervention (Biological)
heparin sodium
Lead sponsor
Laboratório Químico Farmacêutico Bergamo Ltda. (class: industry)
Collaborator
Azidus Brasil (class: industry)

Record details

Record id
cardio:ct-nct01346215
Content hash
f74dbe581e33382c63bcbc872089b71f87db4ca642cbfb303fbed7b2b7b10aa3